olmesartan has been researched along with angiotensin i in 11 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (angiotensin i) | Trials (angiotensin i) | Recent Studies (post-2010) (angiotensin i) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 4,218 | 125 | 1,253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Averill, DB; Brosnihan, KB; Ferrario, CM; Schiffrin, EL; Smith, RD; Yokoyama, H | 1 |
| Agata, J; Hyakkoku, M; Sasaki, H; Shimamoto, K; Shinshi, Y; Taniguchi, S; Ura, N; Yoshida, H | 1 |
| Ferrario, CM; Igase, M; Kohara, K; Miki, T; Nagai, T | 1 |
| Cheng, XW; Hayashi, T; Hu, L; Iguchi, A; Kuzuya, M; Murohara, T; Nakamura, K; Okumura, K; Sasaki, T; Sato, K; Song, H | 1 |
| Hayashi, N; Iwamoto, Y; Oguro, R; Ohishi, M; Rakugi, H; Shiota, A; Takeda, M; Takeya, Y; Tatara, Y; Yamamoto, K | 1 |
| Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Nagata, M; Sukumaran, V; Suzuki, K; Takagi, R; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Hitomi, H; Ichihara, A; Kobori, H; Kohno, M; Masaki, T; Mori, H; Morimoto, S; Murase, M; Nakano, D; Nishiyama, A; Ohmori, K; Ohnishi, K; Pelisch, N | 1 |
| Ishibashi, Y; Matsui, T; Yamagishi, S | 1 |
| Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA | 1 |
| Bai, HY; Chisaka, T; Horiuchi, M; Iwanami, J; Kanno, H; Min, LJ; Mogi, M; Nakaoka, H; Ohshima, K; Tsukuda, K; Wang, XL | 1 |
| Ichikawa, H; Kimura, Y; Narita, I; Narita, M; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H; Yokono, Y | 1 |
11 other study(ies) available for olmesartan and angiotensin i
| Article | Year |
|---|---|
Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiomegaly; Collagen; Disease Progression; Endothelium, Vascular; Heart Rate; Hypertension; Imidazoles; Male; Mesenteric Arteries; Myocardium; Rats; Rats, Inbred SHR; Tetrazoles; Vascular Diseases; Vascular Resistance | 2005 |
Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Gene Expression; Imidazoles; Male; Myocardium; Nitrates; Nitrites; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Tetrazoles; Ventricular Remodeling | 2006 |
Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Aorta, Abdominal; Blood Pressure; Carotid Arteries; Catheterization; Disease Models, Animal; Heart Rate; Hyperplasia; Hypertension; Imidazoles; Male; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Tunica Intima | 2008 |
AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.
Topics: Angiotensin I; Animal Feed; Animals; Apolipoproteins E; Atherosclerosis; Cathepsins; Collagen; Dietary Fats; Elastin; Imidazoles; Macrophages; Male; Mice; Oxidative Stress; Renin-Angiotensin System; Tetrazoles | 2010 |
The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Atherosclerosis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Humans; Imidazoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Monocytes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Peptide Fragments; Peptides; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Receptors, G-Protein-Coupled; Tetrazoles | 2010 |
Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Autoimmune Diseases; Cardiotonic Agents; Endoplasmic Reticulum Stress; Heart Failure; Imidazoles; Inflammation; JNK Mitogen-Activated Protein Kinases; Membrane Glycoproteins; Myocarditis; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Peptidyl-Dipeptidase A; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Receptors, Interleukin-1; RNA, Messenger; Tetrazoles | 2012 |
Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Imidazoles; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Thiazepines | 2013 |
Olmesartan blocks advanced glycation end products-induced vcam-1 gene expression in mesangial cells by restoring Angiotensin-converting enzyme 2 level.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Cell Line; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Imidazoles; Mesangial Cells; Peptide Fragments; Peptidyl-Dipeptidase A; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Superoxides; Tetrazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Cardiomegaly; Epithelial Sodium Channels; Imidazoles; Male; Mice; Mice, Inbred C57BL; Oxadiazoles; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Sodium; Tetrazoles | 2014 |
Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin.
Topics: Albuminuria; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Biomarkers; Blood Pressure; Blotting, Western; Imidazoles; Male; Mice; NADPH Oxidases; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; Tetrazoles | 2018 |